NY-ALVAREZ-&-MARSAL
Leading global professional services firm Alvarez & Marsal (A&M) has announced the promotion of 69 professionals, across Europe and Middle East, India, Latin America, North America, North Asia and Southeast Asia & Australia to the position of Managing Director.
Tony Alvarez II and Bryan Marsal, A&M’s Co-Founders, stated, “Congratulations to all our newly promoted Managing Directors. Their contributions to our core values of integrity, quality, objectivity, fun, personal reward and inclusive diversity are what make A&M unique. Their commitment to help clients maximize value and drive change amidst ongoing macro-economic challenges builds upon our legacy of operational excellence while advancing our results-oriented mission. They, alongside all A&M professionals, are our greatest strength.”
2024 MANAGING DIRECTOR PROMOTIONS
Europe and Middle East
- Cristiano Battelli, Private Equity Performance Improvement -- Milan
- Paul Culham, Global Transaction Advisory Group -- London
- Louis Darrieus, Global Transaction Advisory Group -- Paris
- Steve Green, Debt Advisory -- London
- Josefine Haensel, Corporate Transformation Services -- Hamburg
- Samih Hajar, Global Transaction Advisory Group -- Paris
- Cheng He, Global Transaction Advisory Group -- London
- Michal Kapela, Global Transaction Advisory Group -- Zurich
- Zeeshan Mansoor, Financial Services Industry -- Amsterdam
- Michael Nizet, Financial & Operational Restructuring -- Amsterdam
- Robert Park, Corporate Transformation Services -- London
- Tom Paterson, Debt Advisory -- London
- Adam Paxton, Insolvency -- London
- Felix Schweigger, Private Equity Performance Improvement -- Munich
- Steve Smith, Tax -- London
- Sebastien Trochet, Digital & Technology Services -- Paris
- Yann Varin, Private Equity Performance Improvement -- Paris
- Nick Walton, Tax -- Manchester
India
- Ashish Doshi, Global Transaction Advisory Group -- Mumbai
- Ram Panda, Business Transformation Services -- Mumbai
Latin America
- Guilherme Almeida, Corporate Transformation -- São Paulo
- Luiz Gronau, Infrastructure & Capital Projects (A&M INFRA) -- São Paulo
- Eduardo Magalhaes, Global Disputes and Investigations -- São Paulo
North America
- Richard Behrens, North American Commercial Restructuring -- Los Angeles
- Brett Bergamo, Energy -- Houston
- Amy Best, Global Disputes and Investigations -- Denver
- Matthew Box, Healthcare -- Washington, D.C.
- Aaron Busse, Corporate Performance Improvement -- Atlanta
- Meghan Cardell, Global Disputes and Investigations -- Washington, D.C.
- Evan Colwell, Global Transaction Advisory Group -- Nashville
- Steve Coverick, North American Commercial Restructuring -- Dallas
- Jorge de Los Reyes, Infrastructure & Capital Projects (A&M INFRA) -- Washington, D.C.
- Beata De Zagon, Global Transaction Advisory Group -- Dallas
- Alex Duff, Private Equity Performance Improvement -- New York
- Ryan Duffy, Global Transaction Advisory Group -- Chicago
- Kyle Foust, Tax -- Chicago
- Max Fulton, Private Equity Performance Improvement -- Denver
- Jen Fults, Tax -- New York
- Jeffrey Gerarde, Tax -- Washington, D.C.
- John Hanson, North American Commercial Restructuring -- Dallas
- Sam Jones, Global Transaction Advisory Group -- Chicago
- Andrew Khoo, North American Commercial Restructuring -- New York
- David Knight, Private Equity Performance Improvement -- Houston
- Daniel LaMantia, Private Equity Performance Improvement -- Dallas
- Erin Leveton, Public Sector Services -- Washington, D.C.
- Allen Mahr, North American Commercial Restructuring -- New York
- Matthew Merhan, Corporate Performance Improvement -- Houston
- Derek Myers, Tax -- Atlanta
- Rich Niemerg, North American Commercial Restructuring -- Chicago
- Alan Pender, Energy -- Dallas
- Rob Reid, Infrastructure & Capital Projects (A&M INFRA) -- Atlanta
- Jeffrey Richman, Corporate Finance -- New York
- Brian Rudelson, Tax -- Houston
- Joan Russo, Healthcare -- Miami
- Paul Saftig, Global Transaction Advisory Group -- Chicago
- John Sawyer, Valuation -- Seattle
- Daniel Schmeltz, Corporate Performance Improvement -- Houston
- Jigar Shah, Corporate Performance Improvement -- Los Angeles
- Michael Shanahan, Global Disputes and Investigations -- Philadelphia
- Jeff Swerdlow, Tax -- Denver
- Andrew Thung, Healthcare -- New York
- Jeremy Tilsner, Global Disputes and Investigations -- New York
- Andrey Ulyanenko, Tax -- Miami
- Aaron Umberger, Public Sector Services -- Washington, D.C.
- Mariya Verbitski, Global Transaction Advisory Group -- San Francisco
North Asia
- Dee Chung, Restructuring & Turnaround -- Seoul
- Carmen Yeung, Restructuring & Turnaround -- Hong Kong SAR
Southeast Asia & Australia
- John Sanger, Performance Improvement -- Perth
- Kaustav Sen, Performance Improvement -- Singapore
About Alvarez & Marsal
Companies, investors and government entities around the world turn to Alvarez & Marsal (A&M) for leadership, action and results. Privately held since its founding in 1983, A&M is a leading global professional services firm that provides advisory, business performance improvement and turnaround management services. When conventional approaches are not enough to create transformation and drive change, clients seek our deep expertise and ability to deliver practical solutions to their unique problems.
With over 8,500 people across six continents, we deliver tangible results for corporates, boards, private equity firms, law firms and government agencies facing complex challenges. Our senior leaders, and their teams, leverage A&M’s restructuring heritage to help companies act decisively, catapult growth and accelerate results. We are experienced operators, world-class consultants, former regulators and industry authorities with a shared commitment to telling clients what’s really needed for turning change into a strategic business asset, managing risk and unlocking value at every stage of growth.
To learn more, visit: AlvarezandMarsal.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240109034313/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
